Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Phase 3
Not yet recruiting
- Conditions
- Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 5056
- Registration Number
- NCT07037459
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Phase 1
Not yet recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 380
- Registration Number
- NCT07037758
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Phase 3
Not yet recruiting
- Conditions
- Atherosclerotic Cardiovascular DiseaseOverweightObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12800
- Registration Number
- NCT07037433
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Phase 3
Not yet recruiting
- Conditions
- Small-cell Lung CancerExtensive Stage Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 330
- Registration Number
- NCT07005128
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 272
- Registration Number
- NCT06987695
- Locations
- 🇯🇵
MIH Clinic Yoyogi, Shibuya-ku, Tokyo, Japan
🇯🇵Shinjuku Southern Clinic, Shinjuku-ku, Tokyo, Japan
🇯🇵Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 15
- Registration Number
- NCT06987539
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 120
- Registration Number
- NCT06976372
- Locations
- 🇺🇸
CenExel, Anaheim, California, United States
🇺🇸CenExel Collaborative Neuroscience Research, LLC Los Alamitos, Los Alamitos, California, United States
🇺🇸Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AMG 378Drug: Placebo
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 92
- Registration Number
- NCT06910709
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Dr. Vince Clinical Research, Overland Park, Kansas, United States
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Phase 1
Recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT06898957
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3501
- Registration Number
- NCT06858839
- Locations
- 🇦🇷
Ciprec - Centro de Investigacion y Prevencion Cardiovascular, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇧🇪Hopital de Warquignies, Boussu, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium